Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Methotrexate
Related studies linked through entity extraction aliases.
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cardiac Sarcoidosis Randomized Trial
- Status
- RECRUITING
- Phase
- PHASE3
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE3
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Status
- COMPLETED
- Phase
- PHASE3
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
- Status
- COMPLETED
- Phase
- PHASE2
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3